SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
TMCnet News SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast [December 11, 2020] SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast â Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment â â Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - Â Â â Data to be Presented Today at the San Anton...
Source: tmcnet.com